| 1.23 0.02 (1.65%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.51 | 1-year : | 1.77 |
| Resists | First : | 1.29 | Second : | 1.51 |
| Pivot price | 1.19  |
|||
| Supports | First : | 1.16 | Second : | 1.08 |
| MAs | MA(5) : | 1.23 | MA(20) : | 1.17 |
| MA(100) : | 1.21  |
MA(250) : | 1.3 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 60.6 |
D(3) : | 65.2 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 2.09 | Low : | 0.88 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TELO ] has closed below upper band by 25.7%. Bollinger Bands are 22.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.23 - 1.24 | 1.24 - 1.24 |
| Low: | 1.19 - 1.19 | 1.19 - 1.2 |
| Close: | 1.22 - 1.23 | 1.23 - 1.24 |
Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.
Tue, 22 Sep 2026
Experimental drug found to slow bone cancer cell growth in dog and human lab tests - DVM360
Thu, 17 Sep 2026
Vision gains in fish study link Telomir (NASDAQ: TELO) eye data to its cancer program - Stock Titan
Wed, 16 Sep 2026
Telomir (TELO) investors approve all 2026 votes - Stock Titan
Mon, 14 Sep 2026
Form 8K Telomir Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com UK
Fri, 14 Aug 2026
TELO Q4 2025 Earnings: Deep EPS Miss Underscores Pre-Revenue Challenges - Earnings Miss Streak - careplusvn.com
Mon, 27 Jul 2026
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 46 (%) |
| Held by Institutions | 4.3 (%) |
| Shares Short | 814 (K) |
| Shares Short P.Month | 974 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.9 % |
| Return on Equity (ttm) | -213.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.11 |
| PEG Ratio | 0 |
| Price to Book value | 8.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|